Precision medicine (also known as personalized medicine) uses information about a person’s genes, proteins, and environment to prevent, diagnose, and treat cancer. Precision medicine includes the use of biomarkers, molecular testing, and targeted therapies to deliver a personalized approach to cancer therapy through the use of molecular and genomic information about individual cancers. The National Cancer Institute (NCI) defines precision medicine as “discovering unique therapies that treat an individual’s cancer based on the specific abnormalities of their tumor.”
Optimizing Advanced NSCLC Biomarker Testing, Treatment, and Management
ACCC—in partnership with the American Society for Clinical Pathology—is committed to providing the resources, tools, and education you need to optimize the diagnosis, testing, and management of patients with advanced NSCLC—particularly those with ALK mutations. Receive up to 4.5 hours of CME/CMLE credit as you increase your knowledge in the testing, treatment, and management of patients with advanced NSCLC.
Addresses the role of laboratory medicine professionals and pathologists in biomarker testing, incorporating a review of testing techniques and applications, lab-specific regulations, and the impact of those regulations on biomarker testing.
Learn about open opportunities to participate in an ACCC-supported QI project, then see how ACCC's online self-assessment tools can help identify areas of improvement at your program or practice.
Gain important and practical information for the assessment of measurable residual disease as part of routine clinical practice for patients with chronic lymphocytic leukemia (CLL). This presentation will be valuable for understanding the impact of MRD on treatment decisions and practice patterns, which has promise to lead to major improvements in outcomes for patients with CLL in the very near future.
Genetic Testing and Implementation of Cancer Genomics in Clinical Care was part of the Oncology State Societies at ACCC Virtual Symposium on Friday, November 13, 2020.
Webinar topics include biomarker basics, inherited cancers, laboratory medicine, cost and coverage, and tumor-specific case examples.
Deep dive into the differences between germline and somatic mutations, with case examples, and presentation of findings from the LUNGevity/FORCE patient survey.
We will review current policies and regulations that drive costs related to biomarker testing.
Introduction to cancer biomarkers, relevant terminology, and implications for cancer care.
An insightful and thought-provoking discussion about the expanding role and importance of early engagement of pathologists—the laboratory physicians who guide, develop, and implement biomarker testing.
Genetic counselors—as members of the cancer care team—can help patients better understand their cancer diagnosis, make informed treatment decisions, and navigate the financial costs of testing.
Learn about the current clinical applications of liquid biopsies, associated reimbursement issues, and what you can do to implement these tests at your program.
Learn how genetic healthcare services have adapted to virtual care delivery, and what challenges face its widespread use after the COVID-19 pandemic is over.
Learn about the latest promising breakthroughs in immunotherapy, the challenges facing their widespread use, and what your cancer team needs to know about the future of cancer treatment.
Firas El Chaer, MD, Assistant Professor of Medicine, Department of Hematology and Oncology,
University of Virginia, Emily Couric Clinical Cancer Center
IO Survivorship Templates
Immuno-Oncology in 2021: Committed to the Cutting Edge of Care
IO Virtual Toxicity Article Series
Considerations for Pathology Reporting
Patient-Centered Care: Reporting and Communicating Pathology and Ancillary Test Results
Integration of Pathology with the Cancer Team Infographic
Operational Pathways for Biomarker Testing in NSCLC Environmental Scan
Explore the many terms associated with the different areas and applications of cancer biomarkers.
Biomarker Resource Library
Search this resource bank of nationally available materials relevant to cancer biomarkers and biomarker testing. You may filter by cancer type, area of application, and/or primary audience.
This practical toolkit is centered around the four key elements needed to develop a precision medicine program that successfully incorporates biomarker testing.
MRD Testing Implementation Roadmap
Navigate how to lay the groundwork for MRD testing, prepare your care team, implement testing, and evaluate ongoing progress.
MRD Testing Resource Library
Curated materials to help establish and implement MRD testing for your patients with adult B-cell ALL.
Biomarker Testing Implementation Roadmap for Advanced NSCLC
An innovative tool to implement, expand, and sustain biomarker testing for patients with advanced NSCLC.
Biomarker Testing Resource Library
Curated materials to support the implementation of biomarker testing for patients with advanced NSCLC.
Bispecific Antibodies Resources
Links to recent scholarship and resources that can help practices better serve their patients who may be eligible for TRBA therapy.
As the precision medicine landscape evolves, ACCC supports the multidisciplinary cancer care team with education in the following areas:
A Multidisciplinary Consortium to Advance Genetic Counseling in Oncology
Bringing CAR T-Cell Therapies to Community Oncology
Eliminating Precision Medicine Disparities
Evolving Biomarkers in NSCLC
Integration of MRD Testing: A Pathway for Patients with B-Cell Acute Lymphoblastic Leukemia
Integration of Pathology with the Cancer Care Team
Operational Pathways for Molecular Testing in NSCLC
Preparing Community Providers for Bispecific Antibodies
Quality Improvement in Breast Cancer Through BRCA Testing